Benzinga | Dec 21, 2021 04:32AM EST

Keybanc Upgrades ResMed to Overweight, Announces $302 Price Target

Keybanc analyst Matthew Mishan upgrades ResMed (NYSE:RMD) from Sector Weight to Overweight and announces $302 price target.